RxDoctor Payments Data

Demetrios Agriantonis, MD

Vascular & Interventional Radiology · Newark, DENPI 1063577005

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $10,024 of the $11,764 with a category attached, or 85.2%. Boston Scientific accounts for 61.0% of it on its own, with 24 other manufacturers making up the rest.

$11,764in general payments, 2019–2025

Across 247 payments — averaging $47.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$7K
  • Balt USA, LLC$970
  • Penumbra, Inc.$956
  • Bard Peripheral Vascular, Inc.$597
  • Johnson & Johnson$411
  • Sirtex Medical Inc$288
  • plus $1K from 19 others

What the payments were for

  • Speaking & faculty fees$5505%
  • Travel & lodging$1,19010%
  • Food & beverage$10,02485%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few vascular & interventional radiology providers in Delawareto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$117,766
Medicare patients
716
Services billed
1,386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban18$16,100

Paid to pharmacies, not to this prescriber.

Other vascular & interventional radiology in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →